The effect of reduced-dose Brucella abortus strain 19 vaccination in accredited dairy herds

Beckett, F.W.; MacDiarmid, S.C.

doi:10.1016/0007-1935(85)90046-6

Cited by 31 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the smooth vaccine, B. abortus S19, has been replaced with the rough RB51 vaccine in the US [26], S19 is still used in many countries including India [27] and Argentina [28]. S19 tends to be more pathogenic and can cause abortion in 3.2% of pregnant cows following subcutaneous vaccination [29] or 100% following i.v. injection [30].…”

Section: Discussionmentioning

confidence: 99%

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Yang

Clapp

Thornburg

et al. 2016

Vaccine

View full text Add to dashboard Cite

There remains a need for an improved livestock vaccine for brucellosis since conventional vaccines are only ~70% efficacious, making some vaccinated animals susceptible to Brucella infections. To address this void, a vaccine capable of evoking protective immunity while still being sufficiently attenuated to produce minimal disease, is sought. In this pursuit, the ΔnorD ΔznuA B. abortus-lacZ (termed as znBAZ) was developed to be devoid of functional norD and znuA B. abortus genes, and to contain the lacZ as a marker gene. The results show that znBAZ is highly attenuated in mouse and human macrophages, and completely cleared from mouse spleens within eight weeks post-vaccination. Producing less splenic inflammation, znBAZ is significantly more protective than the conventional RB51 vaccine by more than four orders of magnitude. Vaccination with znBAZ elicits elevated numbers of IFN-γ+, TNF-α+, and polyfunctional IFN-γ+ TNF-α+ CD4+ and CD8+ T cells in contrast to RB51-vaccinated mice, which show reduced numbers of proinflammatory cytokine-producing T cells. These results demonstrate that znBAZ is a highly efficacious vaccine candidate capable of eliciting diverse T cell subsets that confer protection against parenteral challenge with virulent, wild-type B. abortus.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Yang

Clapp

Thornburg

et al. 2016

Vaccine

View full text Add to dashboard Cite

show abstract

“…Another problem with S19 is it can cause abortion if given to cows during pregnancy (Smith and Ficht, 1990), and it is fully virulent for humans (Spink et al, 1962). Subcutaneous immunization with S19 in pregnant cattle can result in a 3.2% abortion rate (Beckett and MacDiarmid, 1985), and intravenous immunization of pregnant cows can lead to 100% abortion (Mingle et al, 1941; Taylor and McDiarmid, 1949). To dampen its virulence, but retain its immunogenicity, some studies have focused on modifying S19 (Robertson et al, 1996; Arenas-Gamboa et al, 2009c; Briones et al, 2001).…”

Section: Live Vaccinesmentioning

confidence: 99%

Progress in Brucella vaccine development

et al. 2012

View full text Add to dashboard Cite

Brucella spp. are zoonotic, facultative intracellular pathogens, which cause animal and human disease. Animal disease results in abortion of fetuses; in humans, it manifests flu-like symptoms with an undulant fever, with osteoarthritis as a common complication of infection. Antibiotic regimens for human brucellosis patients may last several months and are not always completely effective. While there are no vaccines for humans, several licensed live Brucella vaccines are available for use in livestock. The performance of these animal vaccines is dependent upon the host species, dose, and route of immunization. Newly engineered live vaccines, lacking well-defined virulence factors, retain low residual virulence, are highly protective, and may someday replace currently used animal vaccines. These also have possible human applications. Moreover, due to their enhanced safety and efficacy in animal models, subunit vaccines for brucellosis show great promise for their application in livestock and humans. This review summarizes the progress of brucellosis vaccine development and presents an overview of candidate vaccines.

show abstract

“…The B19 vaccine is used worldwide because it is considered safe, immunogenic and easy to make. However, administration of the vaccine has its disadvantages which includes the risk of inducing infection in humans, the possibility of induced abortion in pregnant cows and providing a false positive result in serological tests, which can be avoided by restricting the vaccination to cows aged between 3 and 8 months, and by performing serological tests only after 24 months of age (BECKETT; MC DIARMID, 1985;MEYER, 1985;MONTES et al, 1986;NICOLETTI, 1990). …”

Section: Introductionmentioning

confidence: 99%

Mathematical modeling of bovine brucellosis control using the RB51 vaccine

Souza

Neto

Amaku

et al. 2016

SCA

View full text Add to dashboard Cite

The Brazilian Ministry of Agriculture, Livestock and Food Supply established the National Program for Control and Eradication of Brucellosis and Tuberculosis (PNCEBT) in 2001. One of the main strategies adopted by the program is the mandatory vaccination of heifers between three and eight months of age with the B19 strain. In 2007, Brazil allowed the use of RB51 vaccine in bovine females over 8 months of age as an option for the producer, but kept the B19 strain as a mandatory vaccine. This decision is based on the assumption that combining the two vaccines allows to achieve significant vaccination coverage sooner and, consequently, accelerates the fall speed of prevalence. Thus, this study aimed to measure the impact of the combined use of these two vaccines in reducing the prevalence, using as a tool the mathematical modeling. It was concluded that vaccination by RB51, if adopted as a complement to vaccination by B19, mean decrease in the prevalence of bovine brucellosis in less time. Key words: Bovine brucellosis. Thematical modeling. Vaccine. B19. RB51. ResumoO Ministério da Agricultura Pecuária e Abastecimento brasileiro instituiu o Programa Nacional de Controle e Erradicação da Brucelose e da Tuberculose Animal em 2001. Uma das principais medidas adotadas pelo programa é a vacinação obrigatória de fêmeas entre três e oito meses de idade com a cepa B19. Em 2007, o Brasil permitiu a utilização da vacina RB51 em fêmeas bovinas com mais de 8 anos de idade como uma opção para o produtor, porém manteve como vacina obrigatória a B19 em bezerras de 3 a 8 meses de idade. Essa decisão parte do princípio de que combinando as duas vacinas abrevia-se o tempo para a obtenção de coberturas vacinais expressivas na população de fêmeas em idade de procriar e, consequentemente, acelera-se a velocidade de queda da prevalência. Assim, o presente estudo objetivou medir o impacto do uso combinado dessas duas vacinas na redução da prevalência, utilizando como instrumento a modelagem matemática. Concluiu-se que a vacinação pela RB51, se adotada de forma complementar à vacinação pela B19, significaria queda da prevalência da brucelose bovina em menor intervalo de tempo. Palavras-chave: Brucelose bovina. Modelagem matemática. Vacina. B19. RB51

show abstract

The effect of reduced-dose Brucella abortus strain 19 vaccination in accredited dairy herds

Cited by 31 publications

References 8 publications

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Progress in Brucella vaccine development

Mathematical modeling of bovine brucellosis control using the RB51 vaccine

Contact Info

Product

Resources

About